Linked Life Data

18375772

Source:http://linkedlifedata.com/resource/pubmed/id/18375772

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-3-31
pubmed:abstractText
Strong evidence exists demonstrating the benefits of tight glycemic control in type 1 and type 2 diabetes mellitus patients, but glycemic goals are not adequately achieved for many patients. Advancement in the knowledge surrounding the physiology of endogenous glucoregulatory peptide hormones, such as glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, has led to new therapeutic targets for the treatment of type 2 diabetes mellitus. Dipeptidyl peptidase-4 (DPP-4) inhibitors provide practitioners with a novel mechanism of action to use for combination therapies for the treatment of type 2 diabetes mellitus. This article, part 3 of a 3-part series, reviews the new class of medications known as DPP-4 inhibitors as well as discusses a future buccal insulin formulation, Oral-Lyn, on the horizon for the treatment of diabetes mellitus.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
N
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0145-7217
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
183-200
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:articleTitle
Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.
pubmed:affiliation
PharmD, Department of Pharmacotherapy, College of Pharmacy, Washington State University/Elder Services, 5125 North Market Street, Spokane, WA 99217, USA. jneumiller@wsu.edu
pubmed:publicationType
Journal Article